Preclinical and emerging clinical evidence support the possible use of AMG 510 as a single-agent KRAS (G12C) inhibitor, but preclinical evidence may also support the agent in combination.
Both DRUP and TAPUR have emphasized the importance of documenting the failures, as well as the successes, of the use of off-label therapies in cancer.
A retrospective chart review conducted after implementing an ERAS program demonstrated that improved patient education led to less use of opioids in the immediate postoperative period.
In this study, the most common sites of recurrence following first resection of colorectal liver metastases were the liver (51%) followed by the lung (41%).
Rates for breast, cervical, colorectal cancer screening lower compared with women without diabetes.
This study investigated patient adherence and persistence with trifluridine/tipiracil combination and regorafenib regimens for metastatic colorectal cancer, and also addressed whether sequence of administration had an effect on patient adherence and persistence to the therapies.
Panel issues weak recommendations for options in adults aged 50 to 79 years with no prior screening.
A large, prospective, observational study seeks to assess the real-world outcomes of people who use the at-home colorectal cancer screening test Cologuard.
Mortality risk drops 17 percent with one colonoscopy before diagnosis, 45 percent with three colonoscopies.
A retrospective analysis of more than 7000 patients found a potential association between colorectal cancer, hepatic metastasis, and chronic HBV status.
